KANTOFF AARON 4

What Happened
Aaron Kantoff, a director of Avalo Therapeutics (AVTX), was granted a derivative award covering 20,100 shares on 2026-06-02. The filing reports an acquisition price of $0.00 (derivative), indicating an option/award rather than an open-market purchase or sale. This is a grant of equity compensation, not a sale.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04 (appears timely).
• Transaction type/code: Grant / Award (A); 20,100 shares reported as a derivative.
• Reported price: $0.00 (per the filing).
• Vesting: Footnote F1 — the stock option vests 100% on the first anniversary of the grant, contingent on continued service.
• Shares owned after transaction: Not specified in the information provided.
• No indication in this filing of a 10b5-1 plan, tax withholding, or late filing flag.

Context
This was an equity compensation grant (derivative/option) that does not involve immediate cash proceeds or an open-market trade. Such grants are commonly used for director compensation or retention; they do not by themselves indicate buying or selling intent. The award vests fully after one year subject to continued service, at which point additional filings may show exercises or sales if/when those occur.